- Home
- / Rubius Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Rubius Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.1
2024-07-18
Market Capitalization
$7.5 M
2024-07-18
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|---|---|
| General and administrative expense | 2.4M | 22.0M | 39.9M | 57.2M | 50.3M | 53.0M | 30.8M |
| Operating expense total | 10.9M | 43.3M | 91.7M | 169.6M | 166.4M | 178.4M | |
| EBIT | (10.9M) | (43.3M) | (91.7M) | (169.6M) | (166.4M) | (194.6M) | (178.4M) |
| Interest income | 8.0M | 1.8M | 91.0K | 819.0K | |||
| Interest expense | 149.0K | 309.0K | 2.5M | ||||
| Net Income | (11.0M) | (43.8M) | (89.2M) | (163.5M) | (167.7M) | (196.5M) | (179.7M) |
| EPS | (2.0) |